We report here a 6-month-old boy with severe congenital neutropenia (SCN) successfully treated by cord blood stem cell transplantation (CBSCT) from an unrelated donor. He had recurrent life-threatening respiratory infection due to severe neutropenia that was refractory to recombinant human granulocyte colony-stimulating factor (rhG-CSF). Because he had no HLA-matched sibling and no time to wait for unrelated donor, he received HLA-matched unrelated CBSCT as determined by DNA typing. A total of 6.4 Â 10 7 CB nucleated cells/kg was infused after conditioning with busulfan/horse antihuman thymocyte serum/cyclophosphamide. No GVHD developed under the treatment with cyclosporin A and methyl prednisolone. The neutrophil count reached 0.5 Â 10 9 /l on day 14, reticulocyte 1% on day 13 and platelet count over 50 Â 10 9 /l on day 31. We conclude that unrelated CBSCT can be an indication for some cases of SCN, who have recurrent life-threatening infections and are refractory to rhG-CSF, and have no HLA-matched sibling.
syndrome; rhG-CSF; CBSCT Severe congenital neutropenia (SCN) (Kostmann syndrome) is an inherited hematologic disorder with severe neutropenia from early infancy. 1 The bone marrow usually shows a maturation arrest of myelopoiesis at the level of promyelocyte/myelocyte, and this results in severe neutropenia with an absolute neutrophil count below 0.2 Â 10 9 /l and early onset of frequent life-threatening bacterial infections. Most patients die because of infection, despite improvement in supportive care. Moreover, patients with SCN have an increased susceptibility to myelodysplastic syndrome (MDS) and acute myelogeneous leukemia (AML). Although autosomal recessive inheritance has been suggested for the disease, sporadic or autosomal dominant cases have been reported as well. Some studies indicate that mutations of the gene encoding neutrophil elastase (ELA2 gene) are probably the most common cause for the disease. 2, 3 Recombinant human granulocyte colony-stimulating factor (rhG-CSF) dramatically changed both the prognosis of SCN and the quality of life for patients with SCN. 4, 5 However, in the past few years, prolonged hematopoietic stimulation with rhG-CSF has been suggested to contribute to the development of MDS/AML. For patients who are refractory to rhG-CSF or who develop leukemia, stem cell transplantation (SCT) is the only curative treatment. While there are a few published reports on SCN treated by allogeneic bone marrow transplantation (allo-BMT), no report is available on SCN treated by unrelated cord blood stem cell transplantation (CBSCT). We describe here a 6-month-old boy with SCN successfully treated by unrelated CBSCT.
Case report
A male neonate was born at full term to healthy and nonconsanguineous parents without complication. There was no family history suggesting susceptibility to infection. At day 10, he had peri-umbilical cellulitis due to Escherichia coli and was admitted for 8 days. The day after discharge from the hospital, he had fever and severe respiratory distress. He was found to have severe neutropenia at another hospital. At admission his white blood cell count was 2.0 Â 10 9 /l (st 0%, seg 1%, lym 91%, mo 4%), hemoglobin concentration 14.5g/dl and platelet count 238 Â 10 9 /l. White blood cell count fell to 1.23 Â 10 9 /l and platelet count to 9 Â 10 9 /l the next day. He was critically ill from life-threatening respiratory failure with pneumonia, hemorrhage of lungs, septic shock and DIC. He was immediately intubated and was treated with surfactant-TA and plasma exchange. Because his clinical condition did not recover despite the intensive care, he was administered rhG-CSF at a dosage of 10 mg/kg/day based on the possibility that his state was due to severe neutropenia. However, his neutrophil count remained below 0.2 Â 10 recommended to receive immediate SCT, and was transferred to our hospital.
His general condition at admission was almost good and had no signs of infection. Laboratory examination showed white blood cell count 5.5 Â 10 9 /l (st 0%, seg 0%, ly 23%, mo 73%, eos 4%), hemoglobin 10.9g/dl and platelet count 261 Â 10 9 /l. His chest computed tomography scanning showed infiltration with several huge pneumatoceles at bilateral middle and lower lung fields (Figure 2 ).
There was no HLA-identical donor in his family. CBSCT was planned using HLA-DNA typed completely identical CB, since his condition did not permit waiting for the coordination of unrelated donors. He underwent CBSCT at 6 months. Conditioning regimen consisted of busulfan 4 mg/kg orally four times daily from day À9 to day À6, antilymphocyte globulin 15 mg/kg and cyclophosphamide 50 mg/kg intravenously from day À5 to day À2. Cyclosporin A and methyl prednisolone were used for graftversus-host disease (GVHD) prophylaxis. Total CB nucleated cell count was 6.4 Â 10 7 /kg and the CD34-positive cell count was 3.96 Â 10 5 /kg. rhG-CSF was administered on day 5 after CBSCT. The neutrophil count reached 0.5 Â 10 9 /l on day 14, reticulocyte reached 1% on day 13 and platelet count exceeded 50 Â 10 9 /l on day 31. He received platelet transfusions until day 19. There were no infectious episodes and no GVHD (Figure 3 ). Bone marrow aspiration on day 61 did not show the maturation arrest of neutrophil precursors. He maintains normal hematopoiesis at 32 months after the CBSCT, and his mental and physical development is normal.
Mutation analysis in the ELA2 gene including five exons and their boundaries was performed by sequencing the polymerase chain reaction (PCR)-amplified genomic DNA. No mutation was found.
Discussion
A 6-month-old infant with SCN that was unresponsive to rhG-CSF was successfully treated by unrelated CBSCT. Although he had severe respiratory problems before CBSCT, there were no significant complications.
Survival and quality of life in patients with SCN have been changed dramatically by rhG-CSF treatment. More than 95% of patients are responsive to individual doses of rhG-CSF with increased neutrophils, and reduced infections. 4, 5 However, an apparent increase in the incidence of MDS/AML in SCN has also been observed in the past decade. Thus, the progression to MDS/AML seems to be the natural course of SCN with prolonged survival. On the other hand, some reports suggest that use of rhG-CSF contributes to the progression of MDS/AML in the disease by prolonged hematopoietic stimulation. [6] [7] [8] According to the Severe Chronic Neutropenia International Registry (SCNIR), about 10% of patients with rhG-CSF treatment had developed MDS/AML. Furthermore, most patients who developed MDS/AML had a mutated G-CSF receptor. There are some reports describing that mutations in the intracellular region of the G-CSF receptor gene that interrupt signals required for the maturation of myeloid cells occur spontaneously and are associated with the development of MDS/AML. [8] [9] [10] Current evidence indicates that acquisition of mutations in G-CSF receptor leads to hypersensitivity to G-CSF with proliferation of the host cells.
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After the development of MDS/AML, the prognosis of patients with SCN is extremely poor even if they receive SCT. The mortality rate is 70%, according to SCNIR Unrelated CBSCT for severe congenital neutropenia E Mino et al annual report. On the other hand, the data from the SCNIR showed that the outcome of 11 patients who underwent SCT before development to MDS/AML from 1976 to 1998 was much better than that of patients with MDS/AML. 12 Of 11 patients, eight patients received SCT because of no or partial response to rhG-CSF treatment and one patient because of G-CSF receptor mutation. Stem cell sources of most patients were bone marrows, a few peripheral blood stem cells and one CBSC from HLAidentical family, and one case received unrelated bone marrow transplantation. Only two patients whose donors were HLA-mismatched fathers died from acute GVHD and multiorgan failure. SCNIR concludes that SCT from an HLA-identical sibling is beneficial for SCN patients refractory to rhG-CSF.
In our case, we employed CBSCT, since immediate SCT had been needed for him because his infections were unmanageable and life threatening and the treatment with rhG-CSF was not effective. As far as we have searched, there were no reports on unrelated CBSCT. The benefits of CBSCT are the immediate availability of cells, the large storage, the absence of risk to the donor, and the probability of lower risk of GVHD and transmitting infectious disease. CBSCT is generally not recommended for patients with nonmalignant hematological disease because of graft failure. In our case, there was no delayed hematopoietic recovery and graft failure. This is possibly due to sufficient CB cell transfusion and completely identical HLA-DNA typing CB cells.
We consider that unrelated CBSCT is a reliable treatment for patients with SCN who need emergency SCT and have no HLA-matched sibling. Since most patients who need urgent SCT are infants, they can receive sufficient CB cell transfusion. Unrelated CBSCT for severe congenital neutropenia
